SYRE · NASDAQ
Spyre Therapeutics (SYRE) Stock Price & Fundamentals
Spyre Therapeutics (SYRE) closed at $848.53 on Oct 9, 2026, up 0.13% from the previous close of $847.39.
Share price, past year
1Y +32.65%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $848.53 |
| Sep 30, 2026 | $833.76 |
| Aug 31, 2026 | $830.04 |
| Jul 31, 2026 | $792.15 |
| Jun 30, 2026 | $773.84 |
| May 29, 2026 | $772.08 |
| Apr 30, 2026 | $707.73 |
| Mar 31, 2026 | $739.92 |
| Feb 27, 2026 | $731.64 |
| Jan 30, 2026 | $726.11 |
| Dec 31, 2025 | $693.31 |
| Nov 28, 2025 | $669.73 |
| Oct 31, 2025 | $633.42 |
Key statistics
- Market cap
- $74.73B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- −$178.92M
- Shares outstanding
- 88.1M
- Dividend yield
- —
- 52-week range
- $624.76 – $848.53
Spyre Therapeutics's market cap is $74.73B, based on a share price of $848.53 and 88.1M shares outstanding as of Jun 30, 2026.
Financials
Spyre Therapeutics reported revenue of $0.00 for fiscal 2025.
Spyre Therapeutics reported a net loss of $155.20M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $0.00 | — | −$155.20M | — | — | — |
| FY2024ended Dec 31, 2024 | $0.00 | −100.0% | −$208.02M | — | — | −$157.41M |
| FY2023ended Dec 31, 2023 | $886.00K | −62.0% | −$338.79M | −38,238.2% | $13.76 | −$99.91M |
| FY2022ended Dec 31, 2022 | $2.33M | −87.6% | −$83.82M | −3,598.8% | −$24.86 | −$80.18M |
| FY2021ended Dec 31, 2021 | $18.74M | — | −$65.80M | −351.1% | −$25.02 | −$54.29M |
| FY2020ended Dec 31, 2020 | $0.00 | — | −$80.89M | — | −$1.52 | −$80.06M |
| FY2019ended Dec 31, 2019 | $0.00 | −100.0% | −$78.25M | — | −$2.45 | −$67.18M |
| FY2018ended Dec 31, 2018 | $3.89M | −25.3% | −$44.35M | −1,140.6% | −$2.13 | −$32.62M |
| FY2017ended Dec 31, 2017 | $5.21M | +12.5% | −$27.24M | −523.3% | −$1.80 | −$25.23M |
| FY2016ended Dec 31, 2016 | $4.63M | — | −$21.70M | −468.8% | −$2.22 | −$19.05M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$56.30M | — |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$69.03M | $1.06 |
| Q2 FY2024ended Jun 30, 2024 | $0.00 | — | $0.59 |
| Q1 FY2024ended Mar 31, 2024 | $0.00 | — | $0.72 |
| Q4 FY2023ended Dec 31, 2023 | $0.00 | — | −$22.35 |
| Q3 FY2023ended Sep 30, 2023 | $0.00 | — | $0.86 |
| Q2 FY2023ended Jun 30, 2023 | $688.00K | — | $40.14 |
| Q1 FY2023ended Mar 31, 2023 | $198.00K | — | −$4.89 |
Company profile
- Name
- Spyre Therapeutics, Inc.
- Ticker
- SYRE
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001636282
Recent SEC filings
- Oct 7, 2026
- Sep 8, 2026
- Aug 25, 2026
- Aug 4, 2026
- Aug 4, 2026
- Jun 15, 2026
- Jun 1, 2026
- May 29, 2026
Frequently asked questions
What is Spyre Therapeutics's stock price?
Spyre Therapeutics (SYRE) closed at $848.53 on Oct 9, 2026, up 0.13% from the previous close of $847.39.
What is Spyre Therapeutics's market cap?
Spyre Therapeutics's market cap is $74.73B, based on a share price of $848.53 and 88.1M shares outstanding as of Jun 30, 2026.
How much revenue does Spyre Therapeutics make?
Spyre Therapeutics reported revenue of $0.00 for fiscal 2025.
Does Spyre Therapeutics pay a dividend?
Spyre Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Spyre Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures